Market Report, "Indonesia Pharmaceuticals & Healthcare Report Q2 2011", published

New Healthcare market report from Business Monitor International: "Indonesia Pharmaceuticals & Healthcare Report Q2 2011"
Spread the Word
Listed Under

* Healthcare
* Regards
* Ratings
* Asia
* Pharmaceuticals
* Medicines
* Q211
* Multinational
* Pharmaceutical

* Health
* Medical
* Research

* Massachusetts - US

April 21, 2011 - PRLog -- Asia Pacific's attractiveness to multinational drugmakers is faltering. BMI's Pharmaceuticals & Healthcare Business Environment Ratings (BERs), which assess countries according to their risk/reward profile, reveal that the region's score decreased from 53.1 out of 100 in Q111 to 52.5 in Q211 - a drop of 1.13%. Ratings decreases were also seen in Western Europe (-0.93%) and the Americas (-2.20%). Meanwhile, increases were seen in Central and Eastern Europe (+0.19%) and Middle East/Africa (+3.45%).

In BMI's BER matrix for Q211, Indonesia occupies 12th place of the 17 regional markets surveyed in the Asia Pacific region. The country's pharmaceutical rating stands at 47.4 as its business environment is still plagued by poor infrastructure and weak institutions. Indeed, the infrastructural shortcomings are visible in Indonesia's potholed roads, dilapidated public buildings and, most significantly, schools. Despite an ongoing anti-corruption drive, Indonesia is still ranked only 110th out of 178 countries in Transparency International's 2010 Corruption Perception Index. Moreover, excessive bureaucracy and potential security risks also undermine the country's business environment. Having said this, the current executive remains committed to improving Indonesia's business environment, and the recent transition to democracy has significantly improved its long-term prospects for doing business.

Furthermore, with regards to the pharmaceutical industry, factors such as a high annual market growth, coupled with rising population numbers and a relatively solid economic base are expected to encourage multinationals to invest in the country, despite a risky operating environment.

In 2010, expenditure on medicines in Indonesia reached IDR37,530bn (US$4.13bn). With regards to market size, Indonesia compares well with markets such as the Philippines (US$2.80bn) and Thailand (US$3.96bn), although it falls well below the region's average market size of US$11.9bn. Despite the small market size, we believe demand for drugs will rise over the forecast period due to an increased need for modern medicines, population growth and healthcare service improvements, as well as developing economic conditions.

We have upgraded our forecast for Indonesia's real GDP growth from 5.2% to 5.8% for 2010 on account of the strong Q310 growth print. We believe that factors will remain supportive for domestic demand and project real GDP growth to reach 5.9% in 2011. Private consumption and investment growth will continue to power the economy in 2011 as Indonesia embarks on what we project to be a decade of robust economic growth averaging around 6.4%.

For more information or to purchase this report, go to:

Report Table of Contents:

Executive Summary
SWOT Analysis
- Indonesia Pharmaceutical And Healthcare Industry SWOT
- Indonesia Political SWOT
- Indonesia Economic SWOT
- Indonesia Business Environment SWOT
Pharmaceutical Business Environment Rating
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q211
- Rewards
- Risks
Market Summary - Indonesia
Regulatory Regime
- Intellectual Property Issues
- Generic Drug Legislation
- Labelling Requirements
- Counterfeit and Substandard Drugs
- Free Trade Agreements
- Pricing Regime
- Reimbursement Regime
Industry Trends and Developments
- Epidemiology
- Recent Public Health Developments
- Table: UN Millennium Development Goals
- Avian and Swine Flu
- International Avian Flu Partnerships
- Healthcare System
- Healthcare System Reform
- International Healthcare Collaborations
- Pharmaceutical Retail Sector
- Research and Development
- Herbal Medicines
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Indonesia - Economic Activity, 2006-2015
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015
- Other Healthcare Data and Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
Company Profiles
- PT Kalbe Farma
- PT Bio Farma
- Kimia Farma
- Combiphar PT
- Sanofi-Aventis
- Pfizer
- Novartis
- GlaxoSmithKline (GSK)
- Merck & Co
- Bayer
Country Snapshot: Indonesia Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2000-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2010 (US$)
- Table: Average Annual Manufacturing Wages, 2000-2012 (IDR)
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceuticals Business Environment Ratings
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:*** Email Verified
Tags:Healthcare, Regards, Ratings, Asia, Pharmaceuticals, Medicines, Q211, Multinational, Pharmaceutical
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Daily News
Weekly News

Like PRLog?
Click to Share